IDH2 is altered in 10.54% of acute myeloid leukemia patients with IDH2 Mutation present in 10.52% of all acute myeloid leukemia patients [4].

IDH2 Mutation is an inclusion criterion in 12 clinical trials for acute myeloid leukemia, of which 11 are open and 1 is closed. Of the trials that contain IDH2 Mutation and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open), 4 are phase 1/phase 2 (4 open), 5 are phase 2 (4 open), and 1 is phase 3 (1 open) [5].

IDH2 is altered in 2.3% of glioma patients with IDH2 Mutation present in 2.17% of all glioma patients [4].

IDH2 Mutation is an inclusion criterion in 7 clinical trials for glioma, of which 5 are open and 2 are closed. Of the trials that contain IDH2 Mutation and glioma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 4 are phase 2 (3 open) [5].

IDH2 is altered in 1.02% of malignant solid tumor patients with IDH2 Mutation present in 0.75% of all malignant solid tumor patients [4].

IDH2 Mutation is an inclusion criterion in 7 clinical trials for malignant solid tumor, of which 5 are open and 2 are closed. Of the trials that contain IDH2 Mutation and malignant solid tumor as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 3 are phase 2 (3 open) [5].

IDH2 is altered in 1.92% of malignant glioma patients with IDH2 Mutation present in 1.76% of all malignant glioma patients [4].

IDH2 Mutation is an inclusion criterion in 4 clinical trials for malignant glioma, of which 4 are open and 0 are closed. Of the trials that contain IDH2 Mutation and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [5].

IDH2 is altered in 9.88% of WHO grade II glioma patients with IDH2 Mutation present in 9.88% of all WHO grade II glioma patients [4].

IDH2 Mutation is an inclusion criterion in 2 clinical trials for WHO grade II glioma, of which 2 are open and 0 are closed. Of the trials that contain IDH2 Mutation and WHO grade II glioma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (1 open) [5].

IDH2 is altered in 4.88% of myelodysplastic syndromes patients with IDH2 Mutation present in 4.88% of all myelodysplastic syndromes patients [4].

IDH2 Mutation is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain IDH2 Mutation and myelodysplastic syndromes as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

IDH2 is altered in 4.37% of WHO grade III glioma patients with IDH2 Mutation present in 4.24% of all WHO grade III glioma patients [4].

IDH2 Mutation is an inclusion criterion in 2 clinical trials for WHO grade III glioma, of which 2 are open and 0 are closed. Of the trials that contain IDH2 Mutation and WHO grade III glioma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (1 open) [5].

IDH2 is altered in 3.57% of cholangiocarcinoma patients with IDH2 Mutation present in 3.57% of all cholangiocarcinoma patients [4].

IDH2 Mutation is an inclusion criterion in 2 clinical trials for cholangiocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain IDH2 Mutation and cholangiocarcinoma as inclusion criteria, 2 are phase 2 (1 open) [5].

IDH2 is altered in 1.57% of anaplastic astrocytoma patients with IDH2 Mutation present in 1.34% of all anaplastic astrocytoma patients [4].

IDH2 Mutation is an inclusion criterion in 2 clinical trials for anaplastic astrocytoma, of which 2 are open and 0 are closed. Of the trials that contain IDH2 Mutation and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [5].

IDH2 is altered in 1.1% of breast carcinoma patients with IDH2 Mutation present in 0.32% of all breast carcinoma patients [4].

IDH2 Mutation is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain IDH2 Mutation and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

IDH2 Mutation is an inclusion criterion in 2 clinical trials for ependymoma, of which 2 are open and 0 are closed. Of the trials that contain IDH2 Mutation and ependymoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

IDH2 Mutation is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 1 is open and 1 is closed. Of the trials that contain IDH2 Mutation and multiple myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [5].

IDH2 is altered in 14.67% of angioimmunoblastic T-cell lymphoma patients with IDH2 Mutation present in 14.67% of all angioimmunoblastic T-cell lymphoma patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for angioimmunoblastic T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains IDH2 Mutation and angioimmunoblastic T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

IDH2 is altered in 13.33% of anaplastic oligodendroglioma patients with IDH2 Mutation present in 13.33% of all anaplastic oligodendroglioma patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 is altered in 13.33% of oligodendroglioma patients with IDH2 Mutation present in 13.33% of all oligodendroglioma patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and oligodendroglioma as inclusion criteria, 1 is phase 2 (1 open) [5].

IDH2 is altered in 9.46% of leukemia patients with IDH2 Mutation present in 9.44% of all leukemia patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for leukemia, of which 0 are open and 1 is closed. Of the trial that contains IDH2 Mutation and leukemia as inclusion criteria, 1 is phase 1 (0 open) [5].

IDH2 is altered in 7.14% of oligoastrocytoma patients with IDH2 Mutation present in 7.14% of all oligoastrocytoma patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for oligoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and oligoastrocytoma as inclusion criteria, 1 is phase 2 (1 open) [5].

IDH2 is altered in 6.98% of low grade glioma patients with IDH2 Mutation present in 6.98% of all low grade glioma patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and low grade glioma as inclusion criteria, 1 is phase 3 (1 open) [5].

IDH2 is altered in 5.61% of chronic myelomonocytic leukemia patients with IDH2 Mutation present in 5.61% of all chronic myelomonocytic leukemia patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

IDH2 is altered in 5.48% of mixed glioma patients with IDH2 Mutation present in 5.48% of all mixed glioma patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for mixed glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and mixed glioma as inclusion criteria, 1 is phase 3 (1 open) [5].

IDH2 is altered in 5.35% of hematopoietic and lymphoid malignancy patients with IDH2 Mutation present in 5.33% of all hematopoietic and lymphoid malignancy patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 is altered in 3.73% of myelodysplastic/myeloproliferative neoplasm patients with IDH2 Mutation present in 3.73% of all myelodysplastic/myeloproliferative neoplasm patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 is altered in 2.65% of primary myelofibrosis patients with IDH2 Mutation present in 2.65% of all primary myelofibrosis patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and primary myelofibrosis as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 is altered in 2.74% of diffuse glioma patients with IDH2 Mutation present in 2.59% of all diffuse glioma patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 is altered in 2.41% of myelofibrosis patients with IDH2 Mutation present in 2.41% of all myelofibrosis patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains IDH2 Mutation and myelofibrosis as inclusion criteria, 1 is phase 2 (0 open) [5].

IDH2 is altered in 2.17% of diffuse astrocytoma patients with IDH2 Mutation present in 2.17% of all diffuse astrocytoma patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for diffuse astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and diffuse astrocytoma as inclusion criteria, 1 is phase 3 (1 open) [5].

IDH2 is altered in 2.0% of polycythemia vera, post-polycythemic myelofibrosis phase patients with IDH2 Mutation present in 2.0% of all polycythemia vera, post-polycythemic myelofibrosis phase patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for polycythemia vera, post-polycythemic myelofibrosis phase, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and polycythemia vera, post-polycythemic myelofibrosis phase as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 is altered in 1.98% of high-grade glioma, NOS patients with IDH2 Mutation present in 1.98% of all high-grade glioma, NOS patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 is altered in 1.96% of diffuse midline glioma, H3 K27M-mutant patients with IDH2 Mutation present in 1.96% of all diffuse midline glioma, H3 K27M-mutant patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 is altered in 1.84% of essential thrombocythemia patients with IDH2 Mutation present in 1.84% of all essential thrombocythemia patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for essential thrombocythemia, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and essential thrombocythemia as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 is altered in 1.79% of myelofibrosis transformation in essential thrombocythemia patients with IDH2 Mutation present in 1.79% of all myelofibrosis transformation in essential thrombocythemia patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for myelofibrosis transformation in essential thrombocythemia, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and myelofibrosis transformation in essential thrombocythemia as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 is altered in 1.49% of myeloproliferative neoplasm patients with IDH2 Mutation present in 1.49% of all myeloproliferative neoplasm patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and myeloproliferative neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

IDH2 is altered in 1.35% of lymphoma patients with IDH2 Mutation present in 1.3% of all lymphoma patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains IDH2 Mutation and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

IDH2 is altered in 1.14% of polycythemia vera patients with IDH2 Mutation present in 1.14% of all polycythemia vera patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and polycythemia vera as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 is altered in 1.26% of astrocytoma patients with IDH2 Mutation present in 1.09% of all astrocytoma patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and astrocytoma as inclusion criteria, 1 is phase 2 (1 open) [5].

IDH2 is altered in 1.32% of meningioma patients with IDH2 Mutation present in 1.06% of all meningioma patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and meningioma as inclusion criteria, 1 is phase 2 (1 open) [5].

IDH2 is altered in 1.23% of glioblastoma patients with IDH2 Mutation present in 1.04% of all glioblastoma patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 is altered in 0.93% of primary brain neoplasm patients with IDH2 Mutation present in 0.93% of all primary brain neoplasm patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for primary brain neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and primary brain neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

IDH2 is altered in 1.18% of gastric carcinoma patients with IDH2 Mutation present in 0.71% of all gastric carcinoma patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

IDH2 is altered in 0.67% of clear cell renal cell carcinoma patients with IDH2 Mutation present in 0.67% of all clear cell renal cell carcinoma patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH2 Mutation and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

IDH2 is altered in 1.14% of ovarian carcinoma patients with IDH2 Mutation present in 0.55% of all ovarian carcinoma patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

IDH2 is altered in 0.55% of non-small cell lung carcinoma patients with IDH2 Mutation present in 0.5% of all non-small cell lung carcinoma patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH2 Mutation and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

IDH2 is altered in 0.41% of renal cell carcinoma patients with IDH2 Mutation present in 0.41% of all renal cell carcinoma patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH2 Mutation and renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

IDH2 is altered in 0.38% of gallbladder carcinoma patients with IDH2 Mutation present in 0.38% of all gallbladder carcinoma patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH2 Mutation and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

IDH2 is altered in 0.48% of pancreatic carcinoma patients with IDH2 Mutation present in 0.31% of all pancreatic carcinoma patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

IDH2 is altered in 0.74% of gastrointestinal stromal tumor patients with IDH2 Mutation present in 0.25% of all gastrointestinal stromal tumor patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 0 are open and 1 is closed. Of the trial that contains IDH2 Mutation and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) [5].

IDH2 is altered in 0.2% of pleural mesothelioma patients with IDH2 Mutation present in 0.2% of all pleural mesothelioma patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for pleural mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains IDH2 Mutation and pleural mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [5].

IDH2 is altered in 0.24% of prostate carcinoma patients with IDH2 Mutation present in 0.18% of all prostate carcinoma patients [4].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for acute bilineal leukemia, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and acute bilineal leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and acute biphenotypic leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for central nervous system embryonal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for central nervous system ganglioneuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for central nervous system neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for medulloblastoma, non-WNT/non-SHH, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for medulloblastoma, SHH-activated, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and medulloblastoma, SHH-activated as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for medulloblastoma, WNT-activated, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for medulloepithelioma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH2 Mutation and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains IDH2 Mutation and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [5].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for plasma cell leukemia, of which 0 are open and 1 is closed. Of the trial that contains IDH2 Mutation and plasma cell leukemia as inclusion criteria, 1 is phase 2 (0 open) [5].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for primary central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and primary central nervous system lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

IDH2 Mutation is an inclusion criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Mutation and schwannoma as inclusion criteria, 1 is phase 2 (1 open) [5].